Migraine Drugs Market

Migraine Drugs Market (Treatment - Abortive (Triptans and Ergot Alkoids) and Prophylactic (Botulinum Toxin and Topiramate); Route of Administration - Oral and Injectable; Distribution Channel - Retail Pharmacies and Hospital Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Rep Id : TMRGL31136
  • Published On : Oct 2017
  • No. of Pages : 214
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Migraine Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Market Overview
     4.3. Market Dynamics
            4.3.1. Drivers
                     4.3.1.1. High prevalence of migraine and increasing transition from episodic to chronic migraine
                     4.3.1.2. Increasing investment in R&D and promising pipeline of novel drugs
                     4.3.1.3. Aging population and increasing proportion of female population
                     4.3.1.4. Increasing awareness among patients and high promotional investment by key players
            4.3.2. Restraints
                     4.3.2.1. Fragmented Market with vast availability of generic drugs
                     4.3.2.2. Ongoing investment in alternative therapies
            4.3.3. Opportunities
            4.3.4. Trends
     4.4. Migraine Drugs Market Analysis and Forecast, 2017 – 2025
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s five forces analysis
     4.6. Value Chain Analysis
     4.7. Global Prevalence of Migraine
     4.8. Pipeline Analysis
            4.8.1. Pipeline Analysis: Migraine Treatment Drugs
            4.8.2. Pipeline Analysis: Migraine Treatment Devices
     4.9. Market Outlook

5. Global Migraine Drugs Market Analysis and Forecasts, By Treatment
     5.1. Introduction & Definition
     5.2. Key Findings
     5.3. Market Size (US$ Mn) Forecast, By Treatment
            5.3.1. Abortive
                     5.3.1.1. Triptans
                     5.3.1.2. Ergot Alkaloids
                     5.3.1.3. Others
            5.3.2. Prophylactic
                     5.3.2.1. Botulinum Toxin
                     5.3.2.2. Topiramate
                     5.3.2.3. Others
     5.4. New (Pipeline) Migraine Drugs Market Revenue (US$) Forecast, 2017-2025
     5.5. Market Attractiveness, By Treatment
     5.6. Key Trends

6. Global Migraine Drugs Market Analysis and Forecasts, By Route of Administration
     6.1. Introduction & Definition
     6.2. Key Findings
     6.3. Market Size (US$ Mn) Forecast, By Route of Administration
            6.3.1. Oral
            6.3.2. Injectable
            6.3.3. Other
     6.4. Market Attractiveness, By Route of Administration
     6.5. Key Trends

7. Global Migraine Drugs Market Analysis and Forecasts, By Distribution Channel
     7.1. Introduction & Definition
     7.2. Key Findings
     7.3. Market Size (US$ Mn) Forecast, By Distribution Chanel
            7.3.1. Retail Pharmacies
            7.3.2. Hospital Pharmacies
            7.3.3. Others
     7.4. Market Attractiveness, By Distribution Channel
     7.5. Key Trends

8. Global Migraine Drugs Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Global Market Scenario
     8.3. Market Size (US$ Mn) Forecast, By Region
            8.3.1. North America
            8.3.2. Europe
            8.3.3. Asia Pacific
            8.3.4. Latin America
            8.3.5. Middle East & Africa
     8.4. Market Attractiveness, By Region
     8.5. Key Trends, By Region

9. North America Migraine Drugs Market Analysis and Forecast
     9.1. Key Findings
     9.2. Market Size (US$ Mn) Forecast, By Treatment
            9.2.1. Abortive
                     9.2.1.1. Triptans
                     9.2.1.2. Ergot Alkaloids
                     9.2.1.3. Others
            9.2.2. Prophylactic
                     9.2.2.1. Botulinum Toxin
                     9.2.2.2. Topiramate
                     9.2.2.3. Others
     9.3. Market Size (US$ Mn) Forecast, By Route of Administration
            9.3.1. Oral
            9.3.2. Injectable
            9.3.3. Others
     9.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
            9.4.1. Retail Pharmacies
            9.4.2. Hospital Pharmacies
            9.4.3. Others
     9.5. Market Size by Value (US$ Mn) Forecast, By Country
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis
            9.6.1. By Treatment
            9.6.2. By Route of Administration
            9.6.3. By Distribution Channel
            9.6.4. By Country

10. Europe Migraine Drugs Market Analysis and Forecast
     10.1. Key Findings
     10.2. Market Size (US$ Mn) Forecast, By Treatment
            10.2.1. Abortive
                     10.2.1.1. Triptans
                     10.2.1.2. Ergot Alkaloids
                     10.2.1.3. Others
            10.2.2. Prophylactic
                     10.2.2.1. Botulinum Toxin
                     10.2.2.2. Topiramate
                     10.2.2.3. Others
     10.3. Market Size (US$ Mn) Forecast, By Route of Administration
            10.3.1. Oral
            10.3.2. Injectable
            10.3.3. Others
     10.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
            10.4.1. Retail Pharmacies
            10.4.2. Hospital Pharmacies
            10.4.3. Others
     10.5. Market Size by Value (US$ Mn) Forecast, By Country
            10.5.1. Germany
            10.5.2. France
            10.5.3. U.K.
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe
     10.6. Market Attractiveness Analysis
            10.6.1. By Treatment
            10.6.2. By Route of Administration
            10.6.3. By Distribution Channel
            10.6.4. By Country

11. Asia Pacific Anti-migraine Drugs Market Analysis and Forecast
     11.1. Key Findings
     11.2. Market Size (US$ Mn) Forecast, By Treatment
            11.2.1. Abortive
                     11.2.1.1. Triptans
                     11.2.1.2. Ergot Alkaloids
                     11.2.1.3. Others
            11.2.2. Prophylactic
                     11.2.2.1. Botulinum Toxin
                     11.2.2.2. Topiramate
                     11.2.2.3. Others
     11.3. Market Size (US$ Mn) Forecast, By Route of Administration
            11.3.1. Oral
            11.3.2. Injectable
            11.3.3. Others
     11.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
            11.4.1. Retail Pharmacies
            11.4.2. Hospital Pharmacies
            11.4.3. Others
     11.5. Market Size by Value (US$ Mn) Forecast, By Country
            11.5.1. India
            11.5.2. China
            11.5.3. Japan
            11.5.4. Australia & New Zealand
            11.5.5. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis
            11.6.1. By Treatment
            11.6.2. By Route of Administration
            11.6.3. By Distribution Channel
            11.6.4. By Country

12. Latin America Anti-migraine Drugs Market Analysis and Forecast
     12.1. Key Findings
     12.2. Market Size (US$ Mn) Forecast, By Treatment
            12.2.1. Abortive
                     12.2.1.1. Triptans
                     12.2.1.2. Ergot Alkaloids
                     12.2.1.3. Others
            12.2.2. Prophylactic
                     12.2.2.1. Botulinum Toxin
                     12.2.2.2. Topiramate
                     12.2.2.3. Others
     12.3. Market Size (US$ Mn) Forecast, By Route of Administration
            12.3.1. Oral
            12.3.2. Injectable
            12.3.3. Others
     12.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
            12.4.1. Retail Pharmacies
            12.4.2. Hospital Pharmacies
            12.4.3. Others
     12.5. Market Size by Value (US$ Mn) Forecast, By Country
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis
            12.6.1. By Treatment
            12.6.2. By Route of Administration
            12.6.3. By Distribution Channel
            12.6.4. By Country

13. Middle East and Africa Anti-migraine Drugs Market Analysis and Forecast
     13.1. Key Findings
     13.2. Market Size (US$ Mn) Forecast, By Treatment
            13.2.1. Abortive
                     13.2.1.1. Triptans
                     13.2.1.2. Ergot Alkaloids
                     13.2.1.3. Others
            13.2.2. Prophylactic
                     13.2.2.1. Botulinum Toxin
                     13.2.2.2. Topiramate
                     13.2.2.3. Others
     13.3. Market Size (US$ Mn) Forecast, By Route of Administration
            13.3.1. Oral
            13.3.2. Injectable
            13.3.3. Others
     13.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
            13.4.1. Retail Pharmacies
            13.4.2. Hospital Pharmacies
            13.4.3. Others
     13.5. Market Size by Value (US$ Mn) Forecast, By Country
            13.5.1. Saudi Arabia
            13.5.2. South Africa
            13.5.3. Israel
            13.5.4. Rest of Middle East and Africa
     13.6. Market Attractiveness Analysis
            13.6.1. By Treatment
            13.6.2. By Route of Administration
            13.6.3. By Distribution Channel
            13.6.4. By Country

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.2.1. AstraZeneca Plc.
                     14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.1.2. Product Portfolio
                     14.2.1.3. SWOT Analysis
                     14.2.1.4. Financial Overview
                     14.2.1.5. Strategic Overview
            14.2.2. Allergan Plc.
                     14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.2.2. Product Portfolio
                     14.2.2.3. SWOT Analysis
                     14.2.2.4. Financial Overview
                     14.2.2.5. Strategic Overview
            14.2.3. GlaxoSmithKline Plc.
                     14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.3.2. Product Portfolio
                     14.2.3.3. SWOT Analysis
                     14.2.3.4. Financial Overview
                     14.2.3.5. Strategic Overview
            14.2.4. Novartis AG
                     14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.4.2. Product Portfolio
                     14.2.4.3. SWOT Analysis
                     14.2.4.4. Financial Overview
                     14.2.4.5. Strategic Overview
            14.2.5. Pfizer, Inc.
                     14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.5.2. Product Portfolio
                     14.2.5.3. SWOT Analysis
                     14.2.5.4. Financial Overview
                     14.2.5.5. Strategic Overview
            14.2.6. Valeant Pharmaceuticals International, Inc.
                     14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.6.2. Product Portfolio
                     14.2.6.3. SWOT Analysis
                     14.2.6.4. Financial Overview
                     14.2.6.5. Strategic Overview
            14.2.7. Teva Pharmaceutical Industries, Ltd.
                     14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.7.2. Product Portfolio
                     14.2.7.3. SWOT Analysis
                     14.2.7.4. Financial Overview
                     14.2.7.5. Strategic Overview
            14.2.8. Eli Lilly & Company
                     14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.8.2. Product Portfolio
                     14.2.8.3. SWOT Analysis
                     14.2.8.4. Financial Overview
                     14.2.8.5. Strategic Overview
            14.2.9. Merck & Co., Inc.
                     14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.9.2. Product Portfolio
                     14.2.9.3. SWOT Analysis
                     14.2.9.4. Financial Overview
                     14.2.9.5. Strategic Overview
            14.2.10. Janssen Pharmaceutical Company (Johnson & Johnson)
                     14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.10.2. Product Portfolio
                     14.2.10.3. SWOT Analysis
                     14.2.10.4. Financial Overview
                     14.2.10.5. Strategic Overview
            14.2.11. Endo Pharmaceutical Inc.
                     14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.11.2. Product Portfolio
                     14.2.11.3. SWOT Analysis
                     14.2.11.4. Financial Overview
                     14.2.11.5. Strategic Overview
            14.2.12. Zosano Pharma Corporation
                     14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.12.2. Product Portfolio
                     14.2.12.3. SWOT Analysis
                     14.2.12.4. Financial Overview
                     14.2.12.5. Strategic Overview
            14.2.13. Alder BioPharmaceutical, Inc.
                     14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.13.2. Product Portfolio
                     14.2.13.3. SWOT Analysis
                     14.2.13.4. Financial Overview
                     14.2.13.5. Strategic Overview
            14.2.14. Avanir Pharmaceuticals, Inc.
                     14.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.14.2. Product Portfolio
                     14.2.14.3. SWOT Analysis
                     14.2.14.4. Financial Overview
                     14.2.14.5. Strategic Overview
            14.2.15. Eisai Co., Ltd.
                     14.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.2.15.2. Product Portfolio
                     14.2.15.3. SWOT Analysis
                     14.2.15.4. Financial Overview
                     14.2.15.5. Strategic Overview

List of Tables

Table 01: Pipeline Analysis, Migraine Therapy Drugs (1/3)
Table 02: Pipeline Analysis, Migraine Therapy Drugs (2/3)
Table 03: Pipeline Analysis, Migraine Therapy Drugs (3/3)
Table 04: Pipeline Analysis, Migraine Therapy Devices
Table 05: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 06: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 07: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 08: Global New Chronic Constipation Therapies Market Size (US$) Forecast, 2017-2025
Table 09: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 10: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 11: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 12: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 13: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 14: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 15: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 16: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 18: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 19: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 20: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 21: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 22: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 23: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 24: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 25: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 26: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 27: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 28: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 29: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 30: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 31: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 32: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 33: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 34: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 35: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 36: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 37: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 38: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 39: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 40: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 41: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025

List of Figures

Figure 01: Migraine Drugs Market, by Treatment, Market Size (US$ Mn), 2016 (A)
Figure 02: Migraine Drugs Market Revenue (%), by Route of Administration, 2016 (A)
Figure 03: Migraine Drugs Market Revenue (%), by Rigion, 2016 (A)
Figure 04: Treatment Revenue (%), 2016
Figure 05: Route of Administration Revenue (%), 2016
Figure 06: Distribution Channel Revenue  (%), 2016
Figure 07: Global Migraine Drugs Market Size (US$ Mn) Forecast, 2015–2025
Figure 08 : Global Prevalence of Migraine
Figure 09: Market Value Share, by Treatment (2016)
Figure 10: Market Value Share, by Route of Administration (2016)
Figure 11: Market Value Share, by Distribution Channel (2016)
Figure 12: Global Migraine Drugs Market Value Share, by Treatment, 2016 and 2025
Figure 13: Global Migraine Drugs Market Attractiveness, by Treatment, 2017–2025
Figure 14: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Abortive Treatment, 2015–2025
Figure 15: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prophylactic Treatment, 2015–2025
Figure 16: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Triptans, 2015–2025
Figure 17: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ergot Alkoids, 2015–2025
Figure 18: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Abortive Treatment - Others, 2015–2025
Figure 19: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Botulinum Toxin, 2015–2025
Figure 20: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topiramate, 2015–2025
Figure 21: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prophylactic Treatment - Others, 2015–2025
Figure 22: Global Migraine Drugs Market Value Share, by Route of Administration, 2016 and 2025
Figure 23: Global Migraine Drugs Market Attractiveness, by Route of Administration, 2017–2025
Figure 24: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015–2025
Figure 25: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Injectable, 2015–2025
Figure 26: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 27: Global Migraine Drugs Market Value Share, by Distribution Channel, 2016 and 2025
Figure 28: Global Migraine Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 29: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
Figure 30: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 31: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 32: Global Migraine Drugs Market Value Share, by Region, 2016 and 2025
Figure 33: Global Migraine Drugs Market Attractiveness, by Region, 2017–2025
Figure 34: North America Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 35: North America Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 36: North America Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 37: North America Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 38: North America Migraine Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 39: North America Migraine Drugs Market Attractiveness Analysis, by Treatment
Figure 40: North America Migraine Drugs Market Attractiveness Analysis, by Route of Administration
Figure 41: North America Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 42: North America Migraine Drugs Market Attractiveness Analysis, by Country
Figure 43: Europe Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 44: Europe Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 45: Europe Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 46: Europe Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 47: Europe Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 48: Europe Migraine Drugs Market Attractiveness Analysis, by Treatment
Figure 49: Europe Migraine Drugs Market Attractiveness Analysis, by Route of Administration
Figure 50: Europe Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 51: Europe Migraine Drugs Market Attractiveness Analysis, by Country / Sub-region
Figure 52: Asia Pacific Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 53: Asia Pacific Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 54: Asia Pacific Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 55: Asia Pacific Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 56: Asia Pacific Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 57: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Treatment
Figure 58: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Route of Administration
Figure 59: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 60: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Country
Figure 61: Latin America Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 62: Latin America Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 63: Latin America Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 64: Latin America Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 65: Latin America Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 66: Latin America Migraine Drugs Market Attractiveness Analysis, by Treatment
Figure 67: Latin America Migraine Drugs Market Attractiveness Analysis, by Route of Administration
Figure 68: Latin America Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 69: Latin America Migraine Drugs Market Attractiveness Analysis, by Country / Sub-region
Figure 70: Middle East & Africa Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 71: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 72: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 73: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 74: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 75: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Treatment
Figure 76: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Route of Administration
Figure 77: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
Figure 78: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Country